Interview Series 20th March 2026
From the helm: Amplia (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.
In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.
-
Interview Series 18 Jul 2025
From the helm: DroneShield (ASX:DRO), Oleg Vornik, CEO
-
Interview Series 17 Jul 2025
Meet the Analyst: Daniel Laing, Industrials Analyst, Bell Potter
-
Interview Series 7 Jul 2025
From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director
-
Interview Series 7 Jul 2025
From the helm: Perseus Mining (ASX:PRU), Jeff Quartermaine, CEO
-
Interview Series 26 Jun 2025
From the helm: Elsight (ASX:ELS), Howard Digby, Director
-
Interview Series 4 Jun 2025
From the helm: Flynn Gold (ASX:FG1), Neil Marston, Managing Director
-
Interview Series 3 Jun 2025
From the helm: Linq Minerals, Executive Chairman, Clive Donner
-
Interview Series 9 May 2025
Meet the Analyst: John Hester, Bell Potter Analyst
-
_600_338.png)
Interview Series 18 Mar 2025
7 in 7 healthcare insights: from Bell Potter’s Healthcare conference in Sorrento
-
Interview Series 13 Mar 2025
From the helm: EMVision Medical Devices (ASX:EMV) CEO & Managing Director, Scott Kirkland
-
-min_600_338.png)
Interview Series 7 Feb 2025
From the helm: Opthea Ltd (ASX:OPT) Chief Executive Officer, Fred Guerard
-
Interview Series 18 Oct 2024
From the helm: EROAD Ltd (ASX:ERD) Co-CEO, Mark Heine